

HR 2297

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 29, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 7, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/2297>

Sponsor

Name: Rep. Biggs, Andy [R-AZ-5]

Party: Republican • **State:** AZ • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Crane, Elijah [R-AZ-2]	R · AZ		Mar 29, 2023
Rep. Gaetz, Matt [R-FL-1]	R · FL		Mar 29, 2023
Rep. Good, Bob [R-VA-5]	R · VA		Mar 29, 2023
Rep. Rosendale Sr., Matthew M. [R-MT-2]	R · MT		Mar 29, 2023
Rep. Roy, Chip [R-TX-21]	R · TX		Mar 29, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 7, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 29, 2023)

This bill limits FY2024 funding for the Food and Drug Administration (FDA) Innovation Account, which the FDA uses to implement provisions of the 21st Century Cures Act relating to the development of medical products.

Actions Timeline

- **Apr 7, 2023:** Referred to the Subcommittee on Health.
- **Mar 29, 2023:** Introduced in House
- **Mar 29, 2023:** Referred to the House Committee on Energy and Commerce.